Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) Equity Ratio (2020 - 2025)

Tarsus Pharmaceuticals has reported Equity Ratio over the past 6 years, most recently at 0.61 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.61 for Q4 2025, up 2.57% from a year ago — trailing twelve months through Dec 2025 was 0.61 (up 2.57% YoY), and the annual figure for FY2025 was 0.61, up 2.57%.
  • Equity Ratio for Q4 2025 was 0.61 at Tarsus Pharmaceuticals, down from 0.63 in the prior quarter.
  • Over the last five years, Equity Ratio for TARS hit a ceiling of 0.95 in Q2 2021 and a floor of 0.6 in Q4 2024.
  • Median Equity Ratio over the past 5 years was 0.79 (2023), compared with a mean of 0.78.
  • Biggest five-year swings in Equity Ratio: surged 586.45% in 2021 and later decreased 20.74% in 2024.
  • Tarsus Pharmaceuticals' Equity Ratio stood at 0.93 in 2021, then fell by 9.16% to 0.85 in 2022, then decreased by 12.35% to 0.74 in 2023, then decreased by 19.73% to 0.6 in 2024, then increased by 2.57% to 0.61 in 2025.
  • The last three reported values for Equity Ratio were 0.61 (Q4 2025), 0.63 (Q3 2025), and 0.67 (Q2 2025) per Business Quant data.